Literature DB >> 1698856

Monoclonal antibodies against an HLA-B27-derived peptide react with an epitope present on bacterial proteins.

R B Raybourne1, K M Williams.   

Abstract

The role of molecular mimicry in the spondyloarthropathies was investigated with respect to the epitopes involved. mAb were produced against a synthetic peptide whose sequence was derived from a polymorphic region of the HLA-B27 molecule (amino acids 63-83). Two antibodies (J7F2 and H2B6) were selected for study on the basis of their ability to react with bacterial envelope proteins (ELISA) and B27-positive cells (immunofluorescence). J7F2 reacted preferentially with B27-positive cells and neither antibody reacted with MHC class I negative cells. Based on SDS-PAGE blot analysis of bacterial envelope proteins, the pattern of reactivity for both antibodies (against 36- and 19-kDa proteins) was the same as that for a third monoclonal produced against bacterial envelope and reactive with B27-positive cells. This apparent epitope similarity was investigated by using synthetic peptides to inhibit binding of the monoclonals. The B27 synthetic peptide and a smaller peptide derived from it were efficient inhibitors of antipeptide and antibacterial antibody binding to bacterial Ag and B27-positive cells. These studies provide insight into the molecular basis of cross-reactivity between bacterial proteins and MHC class I molecules.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698856

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment.

Authors:  M Breban; R E Hammer; J A Richardson; J D Taurog
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

2.  The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.

Authors:  J D Taurog; J A Richardson; J T Croft; W A Simmons; M Zhou; J L Fernández-Sueiro; E Balish; R E Hammer
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.